Stockreport

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesi...

Elevai Labs, Inc.  (ELAB) 
PDF Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model.Elevai b [Read more]